Scholar Rock stock falls after FDA issues response letter for SMA drug

Investing.comTuesday, September 23, 2025 at 11:36:03 AM
Scholar Rock stock falls after FDA issues response letter for SMA drug
Scholar Rock's stock has taken a hit following the FDA's recent response letter regarding its SMA drug. This news is significant as it raises concerns about the drug's approval timeline and the company's future prospects in the competitive pharmaceutical market. Investors are closely watching how this will impact Scholar Rock's operations and its ability to bring innovative treatments to patients.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
US FDA declines to approve Scholar Rock’s muscle weakness drug; shares fall
NegativeFinancial Markets
The US FDA has declined to approve Scholar Rock's drug aimed at treating muscle weakness, leading to a significant drop in the company's shares. This decision is crucial as it not only impacts Scholar Rock's financial standing but also affects patients who are in need of effective treatments for muscle-related conditions. The setback highlights the challenges pharmaceutical companies face in bringing new drugs to market and raises questions about the future of similar therapies.
Evercore ISI cuts Kenvue stock price target to $18 on FDA acetaminophen review
NegativeFinancial Markets
Evercore ISI has lowered its price target for Kenvue's stock to $18 following a review by the FDA regarding acetaminophen. This adjustment reflects concerns about the potential impact of regulatory scrutiny on the company's performance. Investors should pay attention to how this news might affect Kenvue's market position and overall investor confidence.
Heartflow stock rises after FDA clearance for Next Gen Plaque Analysis
PositiveFinancial Markets
Heartflow's stock has seen a significant rise following the FDA's clearance for its Next Gen Plaque Analysis technology. This advancement is crucial as it enhances the ability to assess coronary artery disease, potentially leading to better patient outcomes. Investors are optimistic about the company's future, as this approval opens doors for broader market adoption and could significantly impact the healthcare landscape.
Lexicon expects delay in FDA feedback on additional data for its diabetes drug
NegativeFinancial Markets
Lexicon Pharmaceuticals has announced that it anticipates a delay in receiving feedback from the FDA regarding additional data for its diabetes drug. This news is significant as it may impact the timeline for the drug's approval and availability to patients, potentially affecting those who rely on new treatments for diabetes management.
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism
NeutralFinancial Markets
Replimune, a biotech company, is currently navigating challenges with the FDA as it seeks to advance its stock amidst a generally optimistic outlook for the biotech sector. This situation is significant as it highlights the complexities biotech firms face in regulatory processes, which can impact investor confidence and market performance.
Tempus AI stock rises after FDA clearance for RNA sequencing device
PositiveFinancial Markets
Tempus AI's stock has seen a significant rise following the FDA's clearance of its RNA sequencing device. This approval is a major milestone for the company, as it not only validates their innovative technology but also opens up new opportunities in the healthcare market. Investors are optimistic about the potential for increased revenue and growth, making this a noteworthy development in the biotech sector.
Nuvalent completes FDA submission for lung cancer drug zidesamtinib
PositiveFinancial Markets
Nuvalent has successfully submitted its application to the FDA for zidesamtinib, a promising new drug aimed at treating lung cancer. This is a significant step forward in the fight against this prevalent disease, as zidesamtinib could offer new hope to patients who currently have limited treatment options. The FDA's review process will be closely watched, as approval could pave the way for more innovative therapies in oncology.
I used medication to overcome alcohol addiction. I’ve built my business on it
PositiveFinancial Markets
In a powerful personal account, an individual shares how naltrexone helped them overcome alcohol addiction and inspired them to build a successful business. This story highlights the effectiveness of this FDA-approved medication, which is safe and non-addictive, and sheds light on the diverse perspectives within the Alcoholics Anonymous community regarding its use. It matters because it challenges traditional views on addiction treatment and offers hope to many seeking recovery.
Ozempic’s Maker Got Crushed. The Rebound Is Under Way.
PositiveFinancial Markets
Novo Nordisk, the maker of Ozempic, is showing signs of recovery after facing challenges. With a new weight-loss pill on the way and the FDA indicating a stricter approach to compounded knockoffs, the company may be on the verge of a turnaround. This is significant as it highlights the potential for innovation in weight management solutions and the importance of regulatory support in ensuring market integrity.
Exclusive-FDA nicotine pouch pilot to ease manufacturers’ research burden, transcript shows
PositiveFinancial Markets
The FDA is launching a pilot program aimed at easing the research burden on manufacturers of nicotine pouches. This initiative is significant as it could streamline the approval process for new products, encouraging innovation in the market. By reducing the regulatory hurdles, the FDA hopes to foster a safer and more diverse range of nicotine alternatives, which could benefit consumers looking for less harmful options.
Latest from Financial Markets
Fed's Bostic Concerned There's More Inflation Ahead
NegativeFinancial Markets
Federal Reserve Bank of Atlanta President Raphael Bostic has expressed concerns about the potential for rising inflation, emphasizing the need for vigilance ahead of a live recording of the Macro Musings podcast. This is significant as it highlights ongoing worries about economic stability and the Fed's role in managing inflation, which can impact interest rates and overall economic growth.
Trump’s $100,000 H-1B Visa Fee Puts Many Tech Start-Ups in a Bind
NegativeFinancial Markets
The recent decision to impose a $100,000 fee on H-1B visas by the Trump administration has left many tech start-ups struggling to cope. This hefty fee could deter innovation and growth in the tech sector, as smaller companies often rely on these visas to attract skilled talent from abroad. The implications of this policy could stifle competition and hinder the ability of start-ups to thrive in an already challenging economic landscape.
U.S. Mid-Atlantic Factory Activity Declines More Severely as Fed Cuts Rates
NegativeFinancial Markets
The latest report from the Richmond Fed reveals a concerning decline in factory activity in the Mid-Atlantic region, with the manufacturing index dropping significantly from minus seven in August to minus 17 in September. This sharp decline highlights the challenges facing manufacturers and raises questions about the overall economic outlook, especially as the Federal Reserve cuts rates. Understanding these trends is crucial for businesses and policymakers alike, as they navigate the complexities of a changing economic landscape.
Meet Erika Kirk, the 36-year-old CEO of Turning Point USA, who has three degrees, two kids, and a clothing brand
PositiveFinancial Markets
Erika Kirk, at just 36, has stepped into the role of CEO at Turning Point USA, a significant conservative organization, following the tragic assassination of her husband, Charlie Kirk. With three degrees and two children, she embodies resilience and determination. Her leadership is crucial not only for the organization but also for the conservative movement in America, as she brings fresh perspectives and a personal commitment to its mission.
Sonos stock hits 52-week high at $15.92
PositiveFinancial Markets
Sonos stock has reached a 52-week high of $15.92, reflecting strong investor confidence and positive market trends for the company. This milestone is significant as it indicates a recovery and growth potential for Sonos, which has been working to innovate and expand its product offerings. Investors are likely to view this upward trend as a promising sign for future performance.
Fed’s Bowman: Fed needs to be decisive in fending off job market risks
NeutralFinancial Markets
Federal Reserve Governor Michelle Bowman emphasized the importance of the Fed being decisive in addressing potential risks to the job market. Her comments highlight the ongoing challenges the economy faces, particularly in maintaining employment levels amid various uncertainties. This is crucial as it affects not only job seekers but also the overall economic stability.